A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies.

Trial Profile

A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 18 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 01 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top